scholarly journals A multicentre single-blind randomized controlled trial comparing bipolar and monopolar transurethral resection of the prostate

2013 ◽  
Vol 5 (6) ◽  
pp. 385
Author(s):  
Carlos E. Méndez-Probst ◽  
Linda Nott ◽  
Stephen E. Pautler ◽  
Hassan Razvi
Keyword(s):  
Quality Of Life ◽  
Transurethral Resection ◽  
Controlled Trial ◽  
Transrectal Ultrasound ◽  
Life Assessment ◽  
Urinary Flow ◽  
Tissue Specimens ◽  
Single Blind ◽  
Length Of Hospitalization

Introduction: Monopolar transurethral resection of the prostate(TURP) is the gold standard surgical therapy for men with lower urinarytract symptoms due to benign prostatic hyperplasia. Althoughgenerally considered safer, TURP experience is limited in Canada.Methods: Forty-three patients from 5 Canadian centres were randomizedto TURP with either bipolar or monopolar platforms.Patients underwent baseline determinations of American UrologicalAssociation (AUA) symptom score, peak urinary flow rate, postvoidresidual bladder volume and transrectal ultrasound prostatevolume. Primary outcome measures were improvement in AUAsymptom score, quality of life assessment and bother assessment.Secondary outcomes included procedural times, duration of catheterization,length of hospitalization, complications and the degreeof thermal artifact in tissue specimens. Patients were followed for6 months.Results: Twenty-two patients were treated with bipolar and 21 withmonopolar TURP. Preoperative demographics were not statisticallydifferent between groups. Postoperative data collection times wereequivalent in AUA symptom, quality of life, bother and sexualfunction assessments. No differences were observed in the proceduretime (60.7 min, bipolar vs. 47.4, monopolar) or the durationof urethral catheterization (1.5 days, bipolar vs. 1.1, monopolar).More patients in the bipolar group were discharged on the sameday of surgery. There were no differences in the degree of tissuethermal artifact or complication rate.Conclusion: This trial suggests equivalent short-term outcomes formen undergoing monopolar or bipolar TURP.

The Therapeutic Effects of Acupuncture on Patients with Chronic Neck Myofascial Pain Syndrome: A Single-Blind Randomized Controlled Trial

2010 ◽  
Vol 38 (05) ◽  
pp. 849-859 ◽  
Author(s):  
Mei-Yuan Sun ◽  
Ching-Liang Hsieh ◽  
Yung-Yen Cheng ◽  
Hung-Chang Hung ◽  
Tsai-Chung Li ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Randomized Controlled Trial ◽  
Myofascial Pain ◽  
Short Form ◽  
Controlled Trial ◽  
Pain Syndrome ◽  
Myofascial Pain Syndrome ◽  
Randomized Controlled ◽  
Single Blind

Chronic neck myofascial pain syndrome (MPS) is a common disorder seen in clinics. There is no gold standard method to treat myofascial pain. We investigated the effects of acupuncture on patients with chronic neck MPS by a single-blind randomized controlled trial. A total of 35 patients were randomly allocated to an acupuncture group (AG) or a sham acupuncture group (SG). Each subject received acupuncture treatment twice per week for three consecutive weeks. The primary outcome measure was quality of life as assessed with Short Form-36, and secondary outcome measures were neck range of motion (ROM), motion-related pain, and Short-Form McGill Pain Questionnaire (SF-MPQ), as determined by a blinded investigator. The clinical assessments were made before treatment (BT) and after six acupuncture treatments (AT), as well as four weeks (F1) and 12 weeks (F2) after the end of the treatment. A total of 34 patients completed the trial. The results indicated that there is no significant difference in the ROM, motion-related pain, and SF-MPQ scores between AG and SG at AT, F1 and F2 (all p > 0.05). However, AG has greater improvement in physical functioning and role emotional of Short Form-36 quality of life at F2. The results indicate that acupuncture may be used to improve the quality of life in patients with chronic neck MPS.

scholarly journals Effect of a home-based exercise program on functional mobility and quality of life in elderly people: protocol of a single-blind, randomized controlled trial

Trials ◽  
2018 ◽  
Vol 19 (1) ◽  
Author(s):  
Glauber Sá Brandão ◽  
Luís Vicente Franco Oliveira ◽  
Glaudson Sá Brandão ◽  
Anderson Soares Silva ◽  
Antônia Adonis Callou Sampaio ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Randomized Controlled Trial ◽  
Elderly People ◽  
Controlled Trial ◽  
Exercise Program ◽  
Functional Mobility ◽  
Randomized Controlled ◽  
Home Based ◽  
Single Blind

scholarly journals Multicentre, single-blind randomised controlled trial comparing MyndMove neuromodulation therapy with conventional therapy in traumatic spinal cord injury: a protocol study

BMJ Open ◽  
2020 ◽  
Vol 10 (9) ◽  
pp. e039650
Author(s):  
Kim D Anderson ◽  
James R Wilson ◽  
Radha Korupolu ◽  
Jacqueline Pierce ◽  
James M Bowen ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Spinal Cord ◽  
Spinal Cord Injury ◽  
Randomised Controlled Trial ◽  
Controlled Trial ◽  
Cord Injury ◽  
Upper Extremity Function ◽  
Randomised Controlled ◽  
Single Blind

IntroductionThis protocol is describing a multicentre, single-blind randomised controlled trial. The objective is to compare the efficacy of MyndMove therapy versus conventional therapy (CT) in improving upper extremity function in individuals with C4–C7 traumatic, incomplete spinal cord injury (SCI). It is being conducted in two US and two Canadian SCI rehabilitation centres.Methods and analysisSixty people aged 18 years or older with a C4–C7 incomplete (AIS B-D) SCI between 4 months and 8 years postinjury are randomised to receive 40 sessions of MyndMove neuromodulation therapy or CT within a 14-week period of time. Therapy sessions are 1 hour in duration with a dose of 3–5 sessions per week. Assessments occur prior to randomisation, after 20 sessions, after 40 sessions and 10 weeks after the last session. The primary outcome measure is the efficacy of MyndMove therapy versus CT in improving upper extremity function as measured by Spinal Cord Independence Measure III: Self-Care subscore after 40 sessions. Secondary outcomes include: (1) improvements in the SCIM mobility subscore; (2) upper limb functions measured by Graded Redefined Assessment of Strength, Sensibility and Prehension and (3) Toronto Rehab Institute Hand Function Test; (4) To assess safety as measured by serious and non-serious adverse events recorded for participants in both groups of the study population over the duration of the study; (5) to compare the change in quality of life as measured by the Spinal Cord Injury-Quality of Life; and (6) to evaluate the impact on healthcare resource utilisation.Ethics and disseminationAll ethical approvals were obtained prior to enrolling any participants. Dissemination of the results of the study will be made at peer-reviewed academic meetings and through peer-reviewed medical journalsTrial registration numberNCT03439319

scholarly journals Oral 5-ASA Versus Prednisone in Short Term Treatment of Crohn's Disease: A Multicentre Controlled Trial

1990 ◽  
Vol 4 (7) ◽  
pp. 452-457 ◽  
Author(s):  
F Martin ◽  
L Sutherland ◽  
IT Beck ◽  
AH Anderson ◽  
CN Williams ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Treatment Period ◽  
Controlled Trial ◽  
Oral Prednisone ◽  
Life Assessment ◽  
Weekly Dose ◽  
Aminosalicylic Acid

A multicencre randomized controlled trial was designed to compare the efficacy and safety of Eudragit-L coated oral 5-aminosalicylic acid (5-ASA) (Salofalk; lnterfalk) 3 g per day to a 'standard' oral prednisone therapeutic regimen in a 12 week treatment period of uncomplicated attacks of Crohn's ileitis and ileocolitis. Fifty patients with active Crohn's disease (Crohn's disease activity index [CDAI] 200 to 450) were randomized to receive either four 250 mg Eudragit-L-100 coated 5-ASA tablets three times a day for 12 weeks or oral prednisone ( 4 mg tablets) at a sustained 40 mg per day for two weeks followed by a 4 mg/day weekly dose reduction for the 10 subsequent weeks. Efficacy was determined by changes in the calculated CDAI and, as a novel assessment, the McMaster University quality of life index at two, four, six, eight, 10 and 12 weeks. Standard blood and urine values were obtained and physician's assessment completed at each two week visit. Clinical remission was obtained in 12 of 26 patients (46%) in the prednisone group and in nine of 19 (47%) in the 5-ASA group. Treatment failure was observed in three patients in each group. All other patients improved during the treatment period. Patients on prednisone reduced their CDAI scores significantly more rapidly during the first four weeks, but the reduction and maintenance of CDAI scores were similar in both groups for the remainder of the study period. In patients with ileocolitis, prednisone was significantly better than 5-ASA. Quality of life assessment parallelled the changes in CDAI, and appear a valid index. The two therapeutic regimens appear safe and did not disclose any unexpected adverse events or side effects. No significant biological abnormalities were detected in either treatment group. In conclusion, in this small trial, it was found that Salofalk at a dose of 3 g per day appears effective treatment for active Crohn's disease, and it is proposed chat higher doses may be beneficial in more extensive disease (ileocolitis) and during the first four weeks of treatment.

Sign in / Sign up

Export Citation Format

Share Document